BioNTech agreed to buy CureVac for $1.25 billion, expanding its mRNA cancer research and boosting its oncology pipeline.

Aetna Life Insurance Co. received a federal judge’s first approval for a settlement valued at more than $3.4 million and ...

Shares of BioNTech SE were soaring in early Monday trading, after Bristol Myers Squibb Co. made an $11.1 billion splash in the rapidly growing new cancer-drug game. The deal announced by Bristol ...

Javascript must be enabled to use this site. Please enable Javascript in your browser and try again. The Cash Hacks Challenge could help you save money and build ...

The trend is continuing into the new year with Johnson & Johnson reaching a $2 billion deal to acquire clinical ... a developer of targeted cancer therapies, and Novartis is buying autoimmune ...

UW Medicine is no longer covering Aetna-insured patients after the two parties failed to reach a final contract agreement ...

UW Medicine and Aetna did not agree on a new contract before a June 1 deadline, meaning more than 50,000 patients could soon see increases in health care costs or potential provider disruptions. The ...

The deal, which includes $3.5 billion in unconditional payments ... BioNTech said in a statement that the partners were seeking to set a new standard of care in the cancer market segment, now ...

The deal gives both companies rights to study BNT327 in combination with each other's experimental cancer compounds. It also signals Bristol Myers' strategy to bolster its pipeline ahead of upcoming ...

Patients who are pregnant or actively receiving treatment could still retain in-network coverage, according to UW Medicine.